.

Metastatic castration-resistant prostate cancer

LAUR Repository

Show simple item record

dc.contributor.author El-Amm, Joelle
dc.contributor.author Patel, Nihar
dc.contributor.author Freeman, Ashley
dc.contributor.author Aragon-Ching, Jeanny B.
dc.date.accessioned 2017-09-22T12:03:58Z
dc.date.available 2017-09-22T12:03:58Z
dc.date.copyright 2013 en_US
dc.identifier.issn 1179-5549 en_US
dc.identifier.uri http://hdl.handle.net/10725/6242
dc.description.abstract Enzalutamide, previously known as MDV300, is an oral, second-generation androgen receptor (AR) signaling inhibitor or antagonist that was approved by the Food and Drug Administration in 2012 for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) postdocetaxel. Preclinical studies have demonstrated impressive affinity to the AR compared to the first-generation AR inhibitors. The landmark Phase III AFFIRM trial demonstrated improved overall survival benefit compared to placebo in addition to improvement in all tested parameters. Enzalutamide is currently being studied in several trials prechemotherapy and in earlier settings of prostate cancer. This review will discuss the mechanism of action of enzalutamide, its pharmacokinetics, the preclinical and clinical trials that led to its approval, the ongoing clinical trials, its safety and efficacy, as well as patterns of resistance, and discusses its place in therapy within the context of several recently approved agents for mCRPC. en_US
dc.language.iso en en_US
dc.title Metastatic castration-resistant prostate cancer en_US
dc.type Article en_US
dc.description.version Published en_US
dc.title.subtitle critical review of enzalutamide en_US
dc.author.school SOM en_US
dc.author.idnumber 201603787 en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Clinical Medicine Insights: Oncology en_US
dc.journal.volume 7 en_US
dc.article.pages 235-245 en_US
dc.keywords Enzalutamide en_US
dc.keywords Androgen receptor en_US
dc.keywords metastatic castrate resistant prostate cancer en_US
dc.keywords MDV30 en_US
dc.identifier.doi http://dx.doi.org/10.4137/CMO.S11670 en_US
dc.identifier.ctation El-Amm, J., Patel, N., Freeman, A., & Aragon-Ching, J. B. (2013). Metastatic castration-resistant prostate cancer: critical review of enzalutamide. Clinical Medicine Insights. Oncology, 7, 235. en_US
dc.author.email joelle.elamm@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813614/ en_US
dc.author.affiliation Lebanese American University en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR


Advanced Search

Browse

My Account